Marshall Financial Group LLC Has $2.31 Million Position in Eli Lilly and Company $LLY

Key Points

• Marshall Financial Group LLC has reduced its stock holdings in Eli Lilly and Company by 27.0%, ending the second quarter with 2,988 shares valued at approximately $2.3 million.
• Several hedge funds made significant increases in their positions during the first quarter, including PNC Financial Services Group, which raised its stake by 97.5%, owning over 101 million shares worth almost $84 billion.
• Eli Lilly's latest earnings report showed a substantial revenue increase of 37.6% year-over-year, with earnings per share of $6.31, surpassing the consensus estimate by $0.72.

Marshall Financial Group LLC lowered its stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 27.0% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2,988 shares of the company's stock after selling 1,105 shares during the quarter. Marshall Financial Group LLC's holdings in Eli Lilly and Company were worth $2,309,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. WestEnd Advisors LLC grew its holdings in shares of Eli Lilly and Company by 210.0% during the 1st quarter. WestEnd Advisors LLC now owns 31 shares of the company's stock worth $26,000 after purchasing an additional 21 shares during the period. Wealth Preservation Advisors LLC purchased a new stake in shares of Eli Lilly and Company during the 1st quarter worth about $27,000. Citizens National Bank Trust Department grew its holdings in shares of Eli Lilly and Company by 180.0% during the 1st quarter. Citizens National Bank Trust Department now owns 42 shares of the company's stock worth $35,000 after purchasing an additional 27 shares during the period. Financial Gravity Asset Management Inc. purchased a new stake in shares of Eli Lilly and Company during the 1st quarter worth about $40,000. Finally, Mascagni Wealth Management Inc. purchased a new stake in shares of Eli Lilly and Company during the 4th quarter worth about $43,000. Institutional investors and hedge funds own 82.53% of the company's stock.

Insider Buying and Selling at Eli Lilly and Company

In related news, Director Gabrielle Sulzberger acquired 117 shares of the stock in a transaction dated Tuesday, August 12th. The shares were acquired at an average price of $641.18 per share, with a total value of $75,018.06. Following the acquisition, the director owned 2,703 shares in the company, valued at approximately $1,733,109.54. The trade was a 4.52% increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director J Erik Fyrwald bought 1,565 shares of the stock in a transaction on Tuesday, August 12th. The stock was acquired at an average cost of $642.33 per share, for a total transaction of $1,005,246.45. Following the acquisition, the director directly owned 74,578 shares in the company, valued at approximately $47,903,686.74. The trade was a 2.14% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have acquired a total of 4,514 shares of company stock worth $2,894,841 in the last 90 days. Company insiders own 0.13% of the company's stock.

Eli Lilly and Company Stock Down 1.2%

Shares of LLY traded down $9.41 during midday trading on Friday, reaching $753.52. 7,319,147 shares of the stock were exchanged, compared to its average volume of 3,181,974. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $939.86. The firm has a 50 day simple moving average of $738.37 and a 200-day simple moving average of $771.89. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86. The company has a market cap of $713.18 billion, a price-to-earnings ratio of 49.25, a P/E/G ratio of 1.06 and a beta of 0.47.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, topping analysts' consensus estimates of $5.59 by $0.72. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The company had revenue of $15.56 billion during the quarter, compared to the consensus estimate of $14.40 billion. During the same period last year, the business earned $3.92 EPS. The business's quarterly revenue was up 37.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Research analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, September 10th. Stockholders of record on Friday, August 15th were issued a dividend of $1.50 per share. The ex-dividend date of this dividend was Friday, August 15th. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.8%. Eli Lilly and Company's dividend payout ratio is currently 39.22%.

Analysts Set New Price Targets

LLY has been the subject of a number of research reports. Leerink Partnrs cut Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a report on Thursday, August 7th. Deutsche Bank Aktiengesellschaft decreased their price target on Eli Lilly and Company from $1,010.00 to $900.00 and set a "buy" rating for the company in a report on Monday, August 11th. Daiwa Capital Markets cut Eli Lilly and Company from an "outperform" rating to a "neutral" rating and set a $700.00 price target for the company. in a report on Sunday, August 17th. Wall Street Zen upgraded Eli Lilly and Company from a "buy" rating to a "strong-buy" rating in a report on Saturday, August 30th. Finally, Leerink Partners reaffirmed a "market perform" rating and issued a $715.00 target price on shares of Eli Lilly and Company in a research report on Thursday, August 7th. One research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have issued a Hold rating to the company. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $939.61.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.